Glutamate antagonists in neurology;Glutamatantagonisten in der neurologie

Nervenarzt

Volumn 72, Issue 6, 2001, Pages 393-405

  Block, F ^a   Kosinski, C M ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Glutamate antagonists; Glutamate receptor; Neurologic disease; Pathophysiology

Indexed keywords

AMANTADINE; AMPA RECEPTOR; BUDIPINE; DEXTROMETHORPHAN; FELBAMATE; FLUPIRTINE; GABAPENTIN; GLUTAMATE RECEPTOR ANTAGONIST; GLYCOPROTEIN GP 120; LAMOTRIGINE; MAGNESIUM SULFATE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; REMACEMIDE; RILUZOLE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGITATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DIABETIC NEUROPATHY; DISORIENTATION; DRUG EFFICACY; EPILEPSY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; NEUROPROTECTION; PARKINSON DISEASE; POSTHERPETIC NEURALGIA; PSYCHOSIS; RECEPTOR BLOCKING; REVIEW; SPASTICITY;

EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0034985913     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050771     Document Type: Review

References (62)

1. Neuroprotection of the brain during cardiopulmonary bypass: A randomized trial of remacemide during coronary artery bypass in 171 patients
2. Molekularbiologische befunde bei der amyotrophen lateralsklerose
3. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial
4. Aging, energy, and oxidative stress in neurodegenerative diseases
5. Global ischemia and behavioural deficits
6. Neuroprotektion beim schlaganfall
7. Group I metabotropic glutamate receptors: Implications for brain diseases
8. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: Correlation with restricted localisation of NR2B subunit in dorsal horn
9. Felbamate: Clinical and molecular aspects of a unique antiepileptic drug
10. Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial
11. A cure for wind up: NMDA receptor antagonists as potential analgesics
12. Pathobiology of ischaemic stroke: An integrated view
13. The role of excitotoxicity in neurodegenerative disease: Implications for therapy
14. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: A double-blind, cross-over comparison with morphine and placebo
15. Lamotrigine in the treatment of painful diabetic neuropathy
16. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): A light and electron microscopic evaluation of the rat retrosplenial cortex
17. Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions
18. The new antiepileptic drugs: Pharmacological and clinical aspects
19. Gabapentin for the treatment of spasticity in patients with spinal cord injury
20. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis
21. Wind-up of spinal cord neurones and pain sensation: Much ado about something?
22. Adjuvant treatment of Parksinson's disease with budipine: A double-blind trial versus placebo
23. A family of AMPA-selective glutamate receptors
24. Antiglutamate therapies in Huntington's disease
25. Neue therapeutische möglichkeiten mit niederaffinen NMDA-rezeptorantagonisten
26. The N-methyl-D-aspartate receptor channel blocker amantadine does not cause histopathological alterations in human brain tissue
27. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: Striatum and globus pallidus
28. Chorea huntington: Tiermodelle weisen neue hypothesen zu pathophysiologie und therapie
29. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
30. Dopamine/glutamate interactions in Parkinson's disease
31. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia
32. Excitatory amino acids in epilepsy and potential novel therapies
33. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis
34. Glutamate antagonists and Parkinson's disease: A review of clinical data
35. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain
36. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5
37. Mechanisms of action of anti-convulsant agents
38. Safety and tolerability of 619C89 after acute stroke
39. Dose optimization of intravenous magnesium sulfate after acute stroke
40. gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: Prevention by memantine
41. Erfahrungen mit memantine bei der behandlung schwerer spastischer und extrapyramidaler bewegungsstörungen in kombination mit der stereotaktischen operation
42. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia
43. Direct hyperpolarizing action of baclofen on hippocampal pyramidal cells
44. NMDA receptor hypofunction model of schizophrenia
45. Flupirtine, a non-opioid centrally acting analgesic, acts as a NMDA antagonist
46. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: Time-course and mechanisms
47. Neurotransmitter receptors I: The metabotropic glutamate receptors: Structure and functions
48. Riluzole therapy in Huntington's disease (HD)
49. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial
50. A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine
51. Topiramate: Pharmacokinetics and pharmacodynamics
52. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans
53. Mitochondrial dysfunction in movement disorders
54. Muscle relaxant action of excitatory amino acid antagonists
55. The TINS/TiPS lecture. The molecular biology of mammalian glutamate receptor channels
56. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action
57. Metabotropic glutamate receptor subtypes are differentially expressed after transient cerebral ischemia without, during and after tolerance induction in the gerbil hippocampus
58. Tremorlytic activity of budipine in Parkinson's disease
59. A summary of mechanistic hypotheses of gabapentin pharmacology
60. Influence of flupirtine on human lower limb reflexes
61. Pharmacokinetics and safety of the novel amino-3-hydroxy-5- methylisoxazole-4-propionate receptor antagonist YM90 K in healthy men
62. Pharmacological modulation of voltage-gated Na+ channels: A rational and effective strategy against ischemic brain damage